Financial Performance - The company's revenue for Q1 2024 was ¥221,095,436.83, a slight increase of 0.01% compared to ¥221,065,012.52 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥13,017,355.44, representing a decrease of 69.65% from a loss of ¥7,672,898.23 in Q1 2023[5] - Total operating revenue for Q1 2024 was CNY 221,095,436.83, a slight increase from CNY 221,065,012.52 in the previous period[25] - Net loss for Q1 2024 was CNY 13,799,127.37, compared to a net loss of CNY 7,679,632.24 in the same period last year[26] - Basic and diluted earnings per share for Q1 2024 were both CNY -0.0141, compared to CNY -0.0083 in the previous year[26] Cash Flow - The net cash flow from operating activities was negative at ¥53,979,279.20, a decline of 23.59% compared to ¥43,674,374.02 in the previous year[5] - Cash flow from operating activities showed a net outflow of CNY 53,979,279.20, worsening from a net outflow of CNY 43,674,374.02 in the previous year[27] - The net cash flow from financing activities also decreased significantly by 116.59% to ¥-11,982,051.93 from ¥72,231,449.31 in the previous year[16] - The net cash flow from financing activities was negative at -11,982,051.93, compared to a positive 72,231,449.31 in the previous year[28] - Cash inflow from investment activities was CNY 46,025,126.79, down from CNY 55,068,099.15 in the previous period[27] Assets and Liabilities - Total assets decreased by 4.94% to ¥2,242,251,406.69 from ¥2,358,838,216.90 at the end of the previous year[5] - Total current assets decreased from 887,341,759.87 to 782,086,859.51, a decline of approximately 11.8%[21] - Total liabilities decreased from 845,035,166.04 to 753,178,534.73, a reduction of about 10.9%[22] - The total liabilities of the company were CNY 1,244,288,800.47, down from CNY 1,345,275,317.26[23] - Total assets decreased from 2,358,838,216.90 to 2,242,251,406.69, a decline of about 4.9%[22] Investments and Expenses - The company reported a significant increase in construction in progress, rising by 335.58% to ¥9,001,357.44, primarily due to renovations at a subsidiary[10][11] - Investment income for Q1 2024 was negative at ¥1,466,388.87, a decline of 166.41% compared to positive income of ¥2,208,237.86 in the same period last year[12] - Total operating costs increased to CNY 235,210,331.67 from CNY 230,840,986.97, with operating costs specifically rising from CNY 167,798,139.49 to CNY 174,172,301.60[25] - The company reported a significant increase in sales expenses, which rose to CNY 37,371,556.19 from CNY 36,844,698.77[25] - Research and development expenses decreased to CNY 1,475,305.52 from CNY 1,768,801.66, indicating a reduction in investment in innovation[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 62,295[18] - CIMIC INDUSTRIAL INC. holds 37.15% of shares, amounting to 344,206,164 shares, with 100,000,000 shares pledged[18] - The total equity attributable to shareholders of the parent company was CNY 979,450,283.47, a decrease from CNY 992,468,338.54[23] Government Subsidies - The company received government subsidies amounting to ¥1,098,475.12 during the reporting period[7] - Other income increased by 539.20% to ¥1,416,495.58, mainly from government subsidies related to land use tax[12][13] Cash and Cash Equivalents - Cash and cash equivalents decreased from 346,922,089.41 to 266,227,611.31, a decrease of about 23.3%[21] - Cash and cash equivalents at the end of the period decreased to 140,848,040.46 from 165,799,949.86 year-over-year[28] - The beginning cash and cash equivalents balance was 215,527,581.42, compared to 141,167,358.41 in the previous year[28] Other Information - The first quarter report was not audited[29] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending[20] - The impact of exchange rate changes on cash and cash equivalents was a positive 889.33, contrasting with a negative impact of -11,112.98 last year[28]
悦心健康(002162) - 2024 Q1 - 季度财报